RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug targets Hard-to-Treat lymphoma in early trial
Disease control OngoingThis early-phase trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have returned or not improved after standard treatments. The drug is a monoclonal antibody designed to help the immune system fight cancer. The main goals are to find the …
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:35 UTC
-
New drug combo shows promise for patients with relapsed lymphoma
Disease control OngoingThis study tests whether combining two immunotherapy drugs (rituximab and pembrolizumab) with or without a chemotherapy drug (lenalidomide) can shrink tumors in people whose follicular lymphoma or diffuse large B-cell lymphoma has returned after prior treatment. About 53 adults w…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:09 UTC
-
New drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tested a combination of two drugs—pembrolizumab (an immunotherapy) and vorinostat (a targeted therapy)—in 52 adults with certain types of lymphoma that had returned or stopped responding to standard treatments. The main goals were to find the safest dose of…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug combo targets tough lymphoma cases
Disease control TerminatedThis study tests a combination of two drugs, epcoritamab and tazemetostat, in people with a type of blood cancer called follicular lymphoma that has come back or not responded to prior treatments. The goal is to see if the combination is safe and effective at shrinking or elimina…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 19, 2026 12:01 UTC